Robert A. Lazarus mostly deals with Biochemistry, Molecular biology, Binding site, Peptide sequence and Protein structure. As a part of the same scientific study, he usually deals with the Biochemistry, concentrating on Thrombin and frequently concerns with Plasmin and Kallikrein. Robert A. Lazarus interconnects Receptor, Hepatocyte growth factor and Plasma protein binding in the investigation of issues within Molecular biology.
His Binding site research integrates issues from Stereochemistry, Repressor, Hedgehog signaling pathway and Escherichia coli. His biological study spans a wide range of topics, including Platelet aggregation inhibitor, Corynebacterium, Reductase and Glycoprotein. The Serine study combines topics in areas such as Serine protease and Receptor tyrosine kinase.
Robert A. Lazarus mainly focuses on Biochemistry, Molecular biology, Serine protease, Peptide sequence and Stereochemistry. His Enzyme, Kallikrein, Nucleic acid, Amino acid and Proteases study are his primary interests in Biochemistry. His Proteases research is multidisciplinary, relying on both Allosteric regulation, Matriptase and Serine.
His work in Molecular biology tackles topics such as DNA which are related to areas like Hydrolysis. Robert A. Lazarus works mostly in the field of Peptide sequence, limiting it down to topics relating to Platelet aggregation inhibitor and, in certain cases, Platelet membrane glycoprotein, as a part of the same area of interest. His Stereochemistry study which covers Phenylalanine hydroxylase that intersects with Carbon-13 NMR, Tyrosine hydroxylase and Cofactor.
His scientific interests lie mostly in Antibody, Immunology, Biochemistry, Allosteric regulation and Proteases. His work carried out in the field of Immunology brings together such families of science as Cancer research, Receptor tyrosine kinase and Hepatocyte growth factor. His studies deal with areas such as Onartuzumab, Molecular biology, Inflammatory bowel disease and Binding site as well as Receptor tyrosine kinase.
His Biochemistry research focuses on Nucleic acid, Enzyme, Intron, Signal peptide and Hydrolase. In his research on the topic of Allosteric regulation, Cell type and Receptor is strongly related with Tryptase. Robert A. Lazarus has researched Proteases in several fields, including Serine protease, Active site, Serine and Cell biology.
Robert A. Lazarus spends much of his time researching Allosteric regulation, Immunology, Antibody, Enzyme and Proteases. His Antibody research includes elements of Plasma protein binding, Cathepsin, Asthma, Biomarker and Peptide. His Enzyme study combines topics from a wide range of disciplines, such as DNA and Magnesium ion.
His work deals with themes such as Serine and Cell biology, which intersect with Proteases. His study with Active site involves better knowledge in Biochemistry. The study of Biochemistry is intertwined with the study of Magnesium in a number of ways.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors.
Mark S. Dennis;William J. Henzel;Robert M. Pitti;Michael T. Lipari.
Proceedings of the National Academy of Sciences of the United States of America (1990)
Solution structure of kistrin, a potent platelet aggregation inhibitor and GP IIb-IIIa antagonist
Marc Adler;Robert A. Lazarus;Mark S. Dennis;Gerhard Wagner.
Peptide exosite inhibitors of factor VIIa as anticoagulants
Mark S. Dennis;Charles Eigenbrot;Nicholas J. Skelton;Mark H. Ultsch.
Crystal structure of the HGF β‐chain in complex with the Sema domain of the Met receptor
Jennifer Stamos;Robert A Lazarus;Xiaoyi Yao;Daniel Kirchhofer.
The EMBO Journal (2004)
Production of 2-Keto-L-Gulonate, an Intermediate in L-Ascorbate Synthesis, by a Genetically Modified Erwinia herbicola
Stephen Anderson;Cara Berman Marks;Robert Lazarus;Jeffrey Miller.
A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo
Jasvinder K. Atwal;Yongmei Chen;Cecilia Chiu;Deborah L. Mortensen.
Science Translational Medicine (2011)
Interactions between Hedgehog proteins and their binding partners come into view
Philip A. Beachy;Sarah G. Hymowitz;Robert A. Lazarus;Daniel J. Leahy.
Genes & Development (2010)
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
Mark Merchant;Xiaolei Ma;Henry R. Maun;Zhong Zheng.
Proceedings of the National Academy of Sciences of the United States of America (2013)
Structure of the RGD protein decorsin: conserved motif and distinct function in leech proteins that affect blood clotting.
Andrzej M. Krezel;Gerhard Wagner;Jana Seymour-Ulmer;Robert A. Lazarus.
Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1.
Daniel Kirchhofer;Mark Peek;Wei Li;Jennifer Stamos.
Journal of Biological Chemistry (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: